Hard to Treat Diseases, Inc. (HTDS) Targets Merger with Biotechnology Company

Date : 11/12/2010 @ 9:01PM
Source : Marketwired
Stock : Hard To Treat Diseases, Inc. (PN CE) (HTDS)
Quote : 0.0001  0.000099 (9900.00%) @ 7:43PM

Hard to Treat Diseases, Inc. (HTDS) Targets Merger with Biotechnology Company

Hard To Treat Diseases, Inc. (PN CE) (USOTC:HTDS)
Historical Stock Chart

5 Years : From Oct 2014 to Oct 2019

Click Here for more Hard To Treat Diseases, Inc. (PN CE) Charts.

Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) is targeting a merger with a Canadian biotechnology company that deals with blood transfusion products.

This biotechnology company, who wishes to remain anonymous at this stage of negotiations, is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin based blood substitutes. The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.

There is currently a shortfall of blood available for transfusions. Serious harmful side effects exist in the use of stored donor blood; specifically, the loss of Nitric Oxide (NO) from the recipients' blood creates a hazardous condition known as vasoconstriction. Due to the demand for blood and associated transfusions, there are an increasing number of clinical trials and process being developed to counteract the loss of NO from blood.

This up-and-coming biotech company plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.

HTDS has remained silent for the past several months as it worked on this deal is pleased with this merger opportunity and feels that it may be a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.

HTDS expects to be in a position to release the name of the merger candidate and the new appointee officers and all relevant data shortly. The company is of the opinion that this is a significant event that requires a public release.

More details to follow shortly.

About Mina Mar Group:

Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit www.minamargroup.com/ice to learn more.

Mina Mar Marketing Group, MMMG (www.minamargroup.net) offers publicly traded companies a full array of services such as Investor Relations and maintenance investor awareness.

To be included in company's email database for press releases, "Friday Tips", industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts: Investor Relations: 1-647-426-1640; www.minamargroup.net/helpdesk Investor Relations Department Inquiry, www.minamargroup.net (IR), for (M&A) and Corporate Matters, www.minamargroup.com Hard to Treat Diseases Inc.: crobichaud@htdsmedical.com

Latest HTDS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.